A Phase 1 Study of Combotox in Pediatric Patients With Refractory B-lineage Acute Lymphoblastic Leukemia

Larry Herrera(Temple University), John Schindler(The University of Texas Southwestern Medical Center), Victor Gheţie(The University of Texas Southwestern Medical Center), Lisa Gore(Children's Hospital Colorado), Victor Aquino(The University of Texas Southwestern Medical Center), Paul G. Schlegel(Goethe University Frankfurt), Ellen S. Vitetta(Southwestern Medical Center), Bruce Bostrom(Minnesota West Community & Technical College), Glen Lew(Emory University), Eric Sandler(Nemours Children's Clinic)
Journal of Pediatric Hematology/Oncology
November 28, 2009
10.1097/mph.0b013e3181bdf211
Cited by 92

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial
|The Lancet|2012|376
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
|Blood|2003|361
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1987|334
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
|The Journal of Pediatrics|1996|294